NUDT15 c.415C>T Polymorphism Predicts 6-MP Induced Early Myelotoxicity in Patients with Acute Lymphoblastic Leukemia Undergoing Maintenance Therapy

References

• Terwilliger T, Abdul-Hay M. Acute lymphoblastic leukemia: a comprehensive review and 2017 update. Blood Cancer J. 2017;7(6):e577. doi:10.1038/bcj.2017.53
   PubMed Web of Science ®Google Scholar
• Relling MV, Hancock ML, Boyett JM, Pui CH, Evans WE. Prognostic importance of 6-mercaptopurine dose intensity in acute lymphoblastic leukemia. Blood. 1999;93(9):2817–2823.
   PubMed Web of Science ®Google Scholar
• Relling M, Gardner E, Sandborn W, et al. Clinical pharmacogenetics implementation consortium guidelines for thiopurine methyltransferase genotype and thiopurine dosing. Clin Pharmacol Ther. 2011;89(3):387–391. doi:10.1038/clpt.2010.320
   PubMed Web of Science ®Google Scholar
• Yang JJ, Landier W, Yang W, et al. Inherited NUDT15 variant is a genetic determinant of mercaptopurine intolerance in children with acute lymphoblastic leukemia. J Clin Oncol. 2015;33(11):1235–1242. doi:10.1200/JCO.2014.59.4671
   PubMed Web of Science ®Google Scholar
• Moriyama T, Nishii R, Perez-Andreu V, et al. NUDT15 polymorphisms alter thiopurine metabolism and hematopoietic toxicity. Nat Genet. 2016;48(4):367–373. doi:10.1038/ng.3508
   PubMed Web of Science ®Google Scholar
• Relling MV, Schwab M, Whirl-Carrillo M, et al. Clinical pharmacogenetics implementation consortium guideline for thiopurine dosing based on TPMT and NUDT15 genotypes: 2018 update. Clin Pharmacol Ther. 2019;105(5):1095–1105. doi:10.1002/cpt.1304
   PubMed Web of Science ®Google Scholar
• Desire S, Balasubramanian P, Bajel A, et al. Frequency of TPMT alleles in Indian patients with acute lymphatic leukemia and effect on the dose of 6-mercaptopurine. Med Oncol. 2010;27(4):1046–1049. doi:10.1007/s12032-009-9331-8
   PubMed Web of Science ®Google Scholar
• Illangeswaran RSS, Mohanan E, Nisham PN, et al. NUDT15 c.415C>T variant explains 6-MP toxicity in patients with acute lymphoblastic leukemia, 57th Annual Conference of Indian Society of Haematology and Blood Transfusion 2016, Jaipur. Indian J Hematol Blood Transfus. 2016;32(2):373–492. doi:10.1007/s12288-016-0728-1
   Google Scholar
• Ansari M, Sauty G, Labuda M, et al. Polymorphisms in multidrug resistance-associated protein gene 4 is associated with outcome in childhood acute lymphoblastic leukemia. Blood. 2009;114(7):1383–1386. doi:10.1182/blood-2008-11-191098
   PubMed Web of Science ®Google Scholar
• Tanaka Y, Manabe A, Fukushima H, et al. Multidrug resistance protein 4 (MRP4) polymorphisms impact the 6-mercaptopurine dose tolerance during maintenance therapy in Japanese childhood acute lymphoblastic leukemia. Pharmacogenomics J. 2015;15(4):380–384. doi:10.1038/tpj.2014.74
   PubMed Web of Science ®Google Scholar
• Stocco G, Cheok MH, Crews KR, et al. Genetic polymorphism of inosine triphosphate pyrophosphatase is a determinant of mercaptopurine metabolism and toxicity during treatment for acute lymphoblastic leukemia. Clin Pharmacol Ther. 2009;85(2):164–172. doi:10.1038/clpt.2008.154
   PubMed Web of Science ®Google Scholar
• Wan Rosalina WR, Teh LK, Mohamad N, et al. Polymorphism of ITPA 94C>A and risk of adverse effects among patients with acute lymphoblastic leukaemia treated with 6-mercaptopurine. J Clin Pharm Ther. 2012;37(2):237–241. doi:10.1111/j.1365-2710.2011.01272.x
   Web of Science ®Google Scholar
• Kim H, Kang HJ, Kim HJ, et al. Pharmacogenetic analysis of pediatric patients with acute lymphoblastic leukemia: a possible association between survival rate and ITPA polymorphism. PLoS One. 2012;7(9):e45558. doi:10.1371/journal.pone.0045558
   PubMed Web of Science ®Google Scholar
• Devasia AJ, Illangeswaran RSS, Raj IX, George B, Balasubramanian P. NUDT15 polymorphism explains serious toxicity to azathioprine in Indian patients with chronic immune thrombocytopenia and autoimmune hemolytic anemia: a case series. Drug Metab Pers Ther. 2020. doi:10.1515/dmpt-2020-0128
   Google Scholar
• Kodidela S, Dorababu P, Thakkar DN, et al. Association of NUDT15 c.415C>T and FPGS 2572C>T variants with the risk of early hematologic toxicity during 6-MP and low-dose methotrexate-based maintenance therapy in Indian patients with acute lymphoblastic leukemia. Genes (Basel). 2020;11:6. doi:10.3390/genes11060594
   Web of Science ®Google Scholar
• Khera S, Trehan A, Bhatia P, Singh M, Bansal D, Varma N. Prevalence of TPMT, ITPA and NUDT 15 genetic polymorphisms and their relation to 6MP toxicity in north Indian children with acute lymphoblastic leukemia. Cancer Chemother Pharmacol. 2019;83(2):341–348. doi:10.1007/s00280-018-3732-3
   PubMed Web of Science ®Google Scholar
• Shah SAV, Paradkar MU, Desai DC, Ashavaid TF. Preemptive NUDT15 genotyping: redefining the management of patients with thiopurine-induced toxicity. Drug Metab Pers Ther. 2018;33(1):57–60. doi:10.1515/dmpt-2017-0038
   PubMedGoogle Scholar
• Kojima Y, Hirotsu Y, Omata W, et al. Influence of NUDT15 variants on hematological pictures of patients with inflammatory bowel disease treated with thiopurines. World J Gastroenterol. 2018;24(4):511–518. doi:10.3748/wjg.v24.i4.511
   PubMed Web of Science ®Google Scholar
• Common Terminology Criteria for Adverse Events (CTCAE). Protocol Development | CTEP. Available from: https://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm#ctc_60. Accessed October 13, 2020.
   Google Scholar
• Moorman AV, Enshaei A, Schwab C, et al. A novel integrated cytogenetic and genomic classification refines risk stratification in pediatric acute lymphoblastic leukemia. Blood. 2014;124(9):1434–1444. doi:10.1182/blood-2014-03-562918
   PubMed Web of Science ®Google Scholar
• Jain P, Korula A, Deshpande P, et al. Adult acute lymphoblastic leukemia: limitations of intensification of therapy in a developing country. JGO. 2018;4:1–12. doi:10.1200/JGO.17.00014
   Web of Science ®Google Scholar
• Kakuta Y, Kinouchi Y, Shimosegawa T. Pharmacogenetics of thiopurines for inflammatory bowel disease in East Asia: prospects for clinical application of NUDT15 genotyping. J Gastroenterol. 2018;53(2):172–180. doi:10.1007/s00535-017-1416-0
   PubMed Web of Science ®Google Scholar
• Moradveisi B, Muwakkit S, Zamani F, Ghaderi E, Mohammadi E, Zgheib NKITPA. TPMT, and NUDT15 genetic polymorphisms predict 6-mercaptopurine toxicity in middle eastern children with acute lymphoblastic leukemia. Front Pharmacol. 2019;10. doi:10.3389/fphar.2019.00916.
   Web of Science ®Google Scholar
• Tanaka Y, Kato M, Hasegawa D, et al. Susceptibility to 6-MP toxicity conferred by a NUDT15 variant in Japanese children with acute lymphoblastic leukaemia. Br J Haematol. 2015;171(1):109–115. doi:10.1111/bjh.13518
   PubMed Web of Science ®Google Scholar
• Yi ES, Choi YB, Choi R, et al. NUDT15 variants cause hematopoietic toxicity with low 6-TGN levels in children with acute lymphoblastic leukemia. Cancer Res Treat. 2018;50(3):872–882. doi:10.4143/crt.2017.283
   Web of Science ®Google Scholar
• Zhou H, Li L, Yang P, et al. Optimal predictor for 6-mercaptopurine intolerance in Chinese children with acute lymphoblastic leukemia: NUDT15, TPMT, or ITPA genetic variants? BMC Cancer. 2018;18. doi:10.1186/s12885-018-4398-2
   Web of Science ®Google Scholar
• Liu Y, Meng Y, Wang L, Liu Z, Li J, Dong W. Associations between the NUDT15 R139C polymorphism and susceptibility to thiopurine-induced leukopenia in Asians: a meta-analysis. Onco Targets Ther. 2018;11:8309–8317. doi:10.2147/OTT.S177007
   PubMed Web of Science ®Google Scholar
• Schaeffeler E, Jaeger SU, Klumpp V, et al. Impact of NUDT15 genetics on severe thiopurine-related hematotoxicity in patients with European ancestry. Genet Med. 2019;21(9):2145–2150. doi:10.1038/s41436-019-0448-7
   PubMed Web of Science ®Google Scholar
• Yu C-H, Chang Y-H, Wang D-S, et al. Determination of NUDT15 variants by targeted sequencing can identify compound heterozygosity in pediatric acute lymphoblastic leukemia patients. Sci Rep. 2020;10(1):14400. doi:10.1038/s41598-020-71468-y
   Web of Science ®Google Scholar
• Bhatia S, Landier W, Hageman L, et al. Systemic exposure to thiopurines and risk of relapse in children with acute lymphoblastic leukemia: a children’s oncology group study. JAMA Oncol. 2015;1(3):287–295. doi:10.1001/jamaoncol.2015.0245
   PubMed Web of Science ®Google Scholar
• Puangpetch A, Tiyasirichokchai R, Pakakasama S, et al. NUDT15 genetic variants are related to thiopurine-induced neutropenia in Thai children with acute lymphoblastic leukemia. Pharmacogenomics. 2020;21(6):403–410. doi:10.2217/pgs-2019-0177
   Web of Science ®Google Scholar
• Yin D, Xia X, Zhang J, et al. Impact of NUDT15 polymorphisms on thiopurines-induced myelotoxicity and thiopurines tolerance dose. Oncotarget. 2017;8(8):13575–13585. doi:10.18632/oncotarget.14594
   PubMedGoogle Scholar
• Ford LT, Berg JD. Thiopurine S-methyltransferase (TPMT) assessment prior to starting thiopurine drug treatment; a pharmacogenomic test whose time has come. J Clin Pathol. 2010;63(4):288–295. doi:10.1136/jcp.2009.069252
   PubMed Web of Science ®Google Scholar
• Higgs JE, Payne K, Roberts C, Newman WG. Are patients with intermediate TPMT activity at increased risk of myelosuppression when taking thiopurine medications? Pharmacogenomics. 2010;11(2):177–188. doi:10.2217/pgs.09.155
   PubMed Web of Science ®Google Scholar
• Evans WE, Hon YY, Bomgaars L, et al. Preponderance of thiopurine S-methyltransferase deficiency and heterozygosity among patients intolerant to mercaptopurine or azathioprine. J Clin Oncol. 2001;19(8):2293–2301. doi:10.1200/JCO.2001.19.8.2293
   PubMed Web of Science ®Google Scholar
• Sumi S, Marinaki AM, Arenas M, et al. Genetic basis of inosine triphosphate pyrophosphohydrolase deficiency. Hum Genet. 2002;111(4–5):360–367. doi:10.1007/s00439-002-0798-z
   PubMed Web of Science ®Google Scholar
• Atanasova S, Shipkova M, Svinarov D, et al. Analysis of ITPA phenotype-genotype correlation in the Bulgarian population revealed a novel gene variant in exon 6. Ther Drug Monit. 2007;29(1):6–10. doi:10.1097/FTD.0b013e3180308554
   Web of Science ®Google Scholar
• Smid A, Karas-Kuzelicki N, Milek M, Jazbec J, Mlinaric-Rascan I. Association of ITPA genotype with event-free survival and relapse rates in children with acute lymphoblastic leukemia undergoing maintenance therapy. PLoS One. 2014;9(10):e109551. doi:10.1371/journal.pone.0109551
   Web of Science ®Google Scholar
• Krishnamurthy P, Schwab M, Takenaka K, et al. Transporter-mediated protection against thiopurine-induced hematopoietic toxicity. Cancer Res. 2008;68(13):4983–4989. doi:10.1158/0008-5472.CAN-07-6790
   Web of Science ®Google Scholar
• Taylor ZL, Vang J, Lopez-Lopez E, Oosterom N, Mikkelsen T, Ramsey LB. Systematic review of pharmacogenetic factors that influence high-dose methotrexate pharmacokinetics in pediatric malignancies. Cancers. 2021;13(11):2837. doi:10.3390/cancers13112837
   PubMed Web of Science ®Google Scholar
• Schmiegelow K, Nielsen SN, Frandsen TL, Nersting J. Mercaptopurine/methotrexate maintenance therapy of childhood acute lymphoblastic leukemia: clinical facts and fiction. J Pediatr Hematol Oncol. 2014;36(7):503–517. doi:10.1097/MPH.0000000000000206
   PubMed Web of Science ®Google Scholar